The treatment of hidradenitis suppurativa with the glucagon‐like peptide‐1 agonist liraglutide | Zendy

Jennings L. | Zendy; Nestor L. | Zendy; Molloy O. | Zendy; Hughes R. | Zendy; Moriarty B. | Zendy; Kirby B. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

The treatment of hidradenitis suppurativa with the glucagon‐like peptide‐1 agonist liraglutide

Author(s) -

Jennings L.,

Nestor L.,

Molloy O.,

Hughes R.,

Moriarty B.,

Kirby B.

Publication year - 2017

Publication title -

british journal of dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.304

H-Index - 179

eISSN - 1365-2133

pISSN - 0007-0963

DOI - 10.1111/bjd.15233

Subject(s) - liraglutide , hidradenitis suppurativa , medicine , psoriasis , agonist , metabolic syndrome , diabetes mellitus , glucagon like peptide 1 , exenatide , disease , endocrinology , dermatology , type 2 diabetes , receptor

Summary Hidradenitis suppurativa ( HS ) is a cutaneous disease associated with systemic inflammation, obesity and metabolic syndrome. Effective treatment options are limited. The antidiabetic agents, incretins, have been used successfully to treat psoriasis – a disease also associated with metabolic syndrome. We report the use of liraglutide, a glucagon‐like peptide‐1 agonist, in a patient with HS , leading to subsequent weight loss and improvement in disease control. To our knowledge, this is the first report of liraglutide used in the treatment of HS .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research